![]() | ![]() |
Formats:
|
||||||||
Copyright © 2002, American Society for Microbiology Treponema denticola Is Resistant to Human β-Defensins Departments of Pathobiology,1 Medicine, University of Washington, Seattle, Washington 981952 *Corresponding author. Mailing address: Department of Medicine, Box 359779, Harborview Medical Center. 325 Ninth Ave., Seattle, WA 98104. Phone: (206) 341-5362. Fax: (206) 341-5363. E-mail: lukehart/at/u.washington.edu. Received November 8, 2001; Revised January 17, 2002; Accepted March 25, 2002. This article has been cited by other articles in PMC.Abstract Spirochetes, including Treponema denticola, are implicated in the pathogenesis of periodontal disease. Because T. denticola lacks lipopolysaccharides that serve as targets for human β-defensin (hβD) binding, we postulated that T. denticola would resist killing by hβD. We showed that T. denticola is resistant to hβD-1 and -2. Protease inhibitors did not enhance killing of T. denticola by hβD-2, suggesting that degradation of hβD-2 by treponemal proteases is not a major factor in T. denticola resistance. Periodontal disease is a destructive inflammatory condition resulting in tooth loss; severe disease requires clinical intervention and affects 6 million Americans (17, 31). Periodontal disease is linked to cardiovascular disease, as well as delivery of preterm, low-birth-weight infants, increasing its recognition as a public health concern (19, 22, 24). Oral spirochetes, including Treponema denticola, are implicated in the pathogenesis of periodontal disease (2, 6, 15), and spirochetes comprise 40% of the microflora found in diseased sites (16). Microorganisms induce a variety of responses from epithelial cells, including the expression of antimicrobial peptides, such as β-defensins. These small, cationic peptides interact with negatively charged cell wall components of bacteria and fungi, disrupting membrane integrity (9). Human β-defensin 1 (hβD-1) is expressed constitutively by gingival epithelial cells, while hβD-2 expression is induced in response to periodontal microorganisms such as Fusobacterium nucleatum (12, 13). Some antimicrobial peptides have significant in vitro bactericidal activity against periodontal pathogens, including Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, and Eikenella corrodens (20, 21); the role of antimicrobial peptides in controlling periodontal pathogens in vivo is unknown. Defensins are known to interact strongly with lipopolysaccharide (LPS) due to its negative charge. T. denticola lacks a traditional LPS, as do many other spirochetes (25). Further, T. denticola is resistant to polymyxin B, a cationic peptide antibiotic that interacts with LPS (1), at more than 1,000 μg/ml. These facts prompted us to investigate whether T. denticola is resistant to human β-defensins. T. denticola strains ATCC 35405, ATCC 35404, ATCC 33521, and GM-1 (30) were obtained from Pamela Braham (University of Washington) and maintained as previously described (4). Escherichia coli strain DH5α was obtained from Patricia Totten (University of Washington) and maintained in Luria-Bertani (LB) medium at 37°C. Four-day, late-logarithmic-phase cultures of T. denticola and overnight cultures of E. coli were centrifuged at 10,000 × g for 10 min at 20°C. Bacteria were washed once and resuspended in phosphate-buffered saline to yield a final concentration of 107 organisms/ml. Bacteria with or without hβD-1 or -2 (Peptides International, Louisville, Ky., and United Biochemical Research, Inc., Seattle, Wash.) were added to duplicate wells of a 96-well polypropylene plate (Costar) at physiologically relevant concentrations ranging from 0.01 to 100 μg/ml and incubated at 37°C for 4 h (18, 26). Motile treponemes were enumerated by dark-field microscopy. E. coli cells were diluted in distilled H2O and plated on LB agar overnight to enumerate CFU. The percentage of killing was calculated as follows: 100 − [(number of viable treated organisms/number of viable untreated organisms) × 100]. All T. denticola strains tested were significantly less susceptible to killing by either defensin than was E. coli (Fig. (Fig.1).1
Because loss of spirochetal motility does not always correlate with loss of viability, we tested metabolic activity of defensin-exposed T. denticola using Alamar Blue, a dye that is reduced in the presence of actively metabolizing organisms (28). This method has been used successfully to monitor antimicrobial activity against Mycobacterium tuberculosis (8). As there was little difference in hβD-2 sensitivity among strains, T. denticola ATCC 35404 was used for all experiments. Organisms (final concentration, 107/ml) were incubated with 10 μg of hβD-2 per ml or 0.1% sodium dodecyl sulfate for 4 h at 37°C and 5% CO2. A 1/10 volume of Alamar Blue (Biosource, Camarillo, Calif.) was then added, and the bacteria were incubated for an additional 20 h. E. coli was used as a control for hβD-2 activity. Optical density for each well was read on a Dynatech colorimetric plate reader at 570 and 600 nm. Percent reduction was calculated as described previously (8). Results from four experiments confirm that T. denticola ATCC 35404 remains metabolically active after incubation with hβD-2. In a representative experiment, incubation in medium alone showed 72.06% ± 10.01% (mean ± standard error of the mean [SEM]) reduction, while incubation with 10 μg of hβD-2 per ml resulted in 71.57% ± 9.88% reduction. Dead bacteria yielded 12.91% ± 1.49% reduction. These results confirm that under these assay conditions, T. denticola remains metabolically active after treatment with hβD-2. The precise mechanism of killing by β-defensins is unknown. Research with other cationic peptides suggests that secondary targets, such as cytochromes or components of DNA synthesis, may be necessary for killing (14, 29). To determine the ability of T. denticola to replicate following exposure to hβD-2, T. denticola ATCC 35404 cultures at 107 organisms/ml were incubated with and without 10 μg of hβD-2 per ml in GM-1 medium at 37°C and 5% CO2 for 4 h. Cultures were diluted serially in semisolid GM-1 medium (with 0.5% Noble agar and 0.5% gelatin) and incubated anaerobically at 37°C for 1 to 2 weeks (5). E. coli incubated in GM-1 medium was used as a control for hβD-2 activity and was quantitated by serial dilution on LB agar. Two independent experiments demonstrate that T. denticola was not killed by hβD-2 under these assay conditions: untreated treponemes produced 7.2 × 106 ± 4.9 × 106 CFU/ml, while treponemes incubated in the presence of peptides produced 1.8 × 107 ± 1.4 × 107 CFU/ml (P = 0.55, Student's two-tailed t test assuming unequal variances). Further, colony size for the hβD-2-treated treponemes was equivalent to that for untreated treponemes, suggesting that there was no sublethal effect on growth. E. coli incubated with hβD-2 in this medium was killed as readily as in phosphate-buffered saline, suggesting that the GM-1 medium itself did not inhibit the activity of hβD-2 (data not shown). One reason for T. denticola's resistance to β-defensins may be that the peptides are degraded or inactivated. The proteases of T. denticola are known to degrade several host proteins and bioactive peptides (3, 7, 10, 11, 23, 27). To test the hypothesis that T. denticola can degrade hβD-2, thus preventing its activity, we examined the effect of protease inhibitors on survival of T. denticola exposed to hβD-2. T. denticola ATCC 35404 and 10 μg of hβD-2 per ml were incubated in the presence or absence of final concentrations of 100 μM chymostatin (Sigma Chemicals, St. Louis, Mo.) at 37°C and 5% CO2 for 4 h. Viable bacteria were enumerated by dark-field microscopy (T. denticola) or plate counts (E. coli). Killing of T. denticola was not enhanced in the presence of chymostatin, which inhibits the major outer membrane-associated protease of T. denticola, dentilisin (Fig. (Fig.2A).2A
In conclusion, we have demonstrated that T. denticola is resistant to killing by human β-defensins, that this resistance exists across strains, and that this resistance is not due to inactivation of the defensins by treponemal proteases. Spirochetes are frequently seen in close association with the epithelium, and resistance to the elevated concentrations of β-defensins at this interface may explain the preponderance of spirochetes observed at those sites in periodontal lesions. The resistance of T. denticola to β-defensins may confer a survival advantage for T. denticola, allowing colonization and persistence in the periodontal pocket. ADDENDUM IN PROOF The resistance to human β-defensin 2 by Treponema denticola tested in low-sodium (10 μM) buffer was equal to that seen in phosphate-buffered saline. Acknowledgments We thank Richard Darveau and Brian Bainbridge for helpful discussions. C.A.B. was supported by NRSA Institutional Research training grant T32 DE 07063. Notes Editor: V. J. DiRita REFERENCES 1. Abramson, I. J., and R. M. Smibert. 1971. Bactericidal activity of antimicrobial agents for treponemes. Br. J. Vener. Dis. 47:413-418. [PubMed] 2. Armitage, G. C., W. R. Dickinson, R. S. Jenderseck, S. M. Levine, and D. W. Chambers. 1982. Relationship between the percentage of subgingival spirochetes and the severity of periodontal disease. J. Periodontol. 53:550-556. [PubMed] 3. Beausejour, A., N. Deslauriers, and D. Grenier. 1997. Activation of the interleukin-1β precursor by Treponema denticola: a potential role in chronic inflammatory periodontal diseases. Infect. Immun. 65:3199-3202. [PubMed] 4. Blakemore, R. P., and E. Canale-Parola. 1976. Arginine catabolism by Treponema denticola. J. Bacteriol. 128:616-622. [PubMed] 5. Chan, E. C., A. De Ciccio, R. McLaughlin, A. Klitorinos, and R. Siboo. 1997. An inexpensive solid medium for obtaining colony-forming units of oral spirochetes. Oral Microbiol. Immunol. 12:372-376. [PubMed] 6. Darveau, R. P., A. Tanner, and R. C. Page. 2000. The microbial challenge in periodontitis. Periodontology 14:12-32. 7. Deng, Q. D., Y. Han, X. Xia, and H. K. Kuramitsu. 2001. Effects of the oral spirochete Treponema denticola on interleukin-8 expression from epithelial cells. Oral Microbiol. Immunol. 16:185-187. [PubMed] 8. Franzblau, S. G., R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson, and R. H. Gilman. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362-366. [PubMed] 9. Ganz, T. 2001. Antimicrobial proteins and peptides in host defense. Semin. Respir. Infect. 16:4-10. [PubMed] 10. Grenier, D. 1996. Degradation of host protease inhibitors and activation of plasminogen by proteolytic enzymes from Porphyromonas gingivalis and Treponema denticola. Microbiology 142:955-961. [PubMed] 11. Grenier, D., and D. Mayrand. 2001. Cleavage of human immunoglobulin G by Treponema denticola. Anaerobe 7:1-4. 12. Krisanaprakornkit, S., J. R. Kimball, A. Weinberg, R. P. Darveau, B. W. Bainbridge, and B. A. Dale. 2000. Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect. Immun. 68:2907-2915. [PubMed] 13. Krisanaprakornkit, S., A. Weinberg, C. N. Perez, and B. A. Dale. 1998. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect. Immun. 66:4222-4228. [PubMed] 14. Lichtenstein, A. K., T. Ganz, T. M. Nguyen, M. E. Selsted, and R. I. Lehrer. 1988. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J. Immunol. 140:2686-2694. [PubMed] 15. Loesche, W. J. 1988. The role of spirochetes in periodontal disease. Adv. Dent. Res. 2:275-283. [PubMed] 16. Loesche, W. J. 1988. The spirochetes, p. 228-236. In M. G. Newman and R. J. Nisengard (ed.), Oral microbiology and immunology. Saunders, Philadelphia, Pa. 17. Loesche, W. J., and N. S. Grossman. 2001. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin. Microbiol. Rev. 14:727-752. [PubMed] 18. Mathews, M., H. P. Jia, J. M. Guthmiller, G. Losh, S. Graham, G. K. Johnson, B. F. Tack, and P. B. McCray, Jr. 1999. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect. Immun. 67:2740-2745. [PubMed] 19. Meyer, D. H., and P. M. Fives-Taylor. 1998. Oral pathogens: from dental plaque to cardiac disease. Curr. Opin. Microbiol. 1:88-95. [PubMed] 20. Miyasaki, K. T., A. L. Bodeau, M. E. Selsted, T. Ganz, and R. I. Lehrer. 1990. Killing of oral, gram-negative, facultative bacteria by the rabbit defensin, NP-1. Oral Microbiol. Immunol. 5:315-319. [PubMed] 21. Miyasaki, K. T., R. Iofel, A. Oren, T. Huynh, and R. I. Lehrer. 1998. Killing of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia by protegrins. J. Periodontal Res. 33:91-98. [PubMed] 22. Offenbacher, S., H. L. Jared, P. G. O'Reilly, S. R. Wells, G. E. Salvi, H. P. Lawrence, S. S. Socransky, and J. D. Beck. 1998. Potential pathogenic mechanisms of periodontitis associated pregnancy complications. Ann. Periodontol. 3:233-250. [PubMed] 23. Pederson, E. D., B. L. Lamberts, and I. L. Shklair. 1988. Susceptibility of fibronectin to degradation by various gram-negative and gram-positive oral micro-organisms. Microbios 53:83-90. [PubMed] 24. Satcher, D. S. 2000. Linkages with general health, p. 95-127. In Oral health in America: a report of the surgeon general. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, Rockville, Md. 25. Schultz, C. P., V. Wolf, R. Lange, E. Mertens, J. Wecke, D. Naumann, and U. Zahringer. 1998. Evidence for a new type of outer membrane lipid in oral spirochete Treponema denticola. Functioning permeation barrier without lipopolysaccharides. J. Biol. Chem. 273:15661-15666. [PubMed] 26. Shi, J., G. Zhang, H. Wu, C. Ross, F. Blecha, and T. Ganz. 1999. Porcine epithelial beta-defensin 1 is expressed in the dorsal tongue at antimicrobial concentrations. Infect. Immun. 67:3121-3127. [PubMed] 27. Sorsa, T., T. Ingman, K. Suomalainen, M. Haapasalo, Y. T. Konttinen, O. Lindy, H. Saari, and V. J. Uitto. 1992. Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type interstitial collagenases. Infect. Immun. 60:4491-4495. [PubMed] 28. Stapleton, J. T., L. V. Stamm, and P. J. Bassford, Jr. 1985. Potential for development of antibiotic resistance in pathogenic treponemes. Rev. Infect. Dis. 7(Suppl. 2):S314-S317. [PubMed] 29. Wachinger, M., A. Kleinschmidt, D. Winder, N. von Pechmann, A. Ludvigsen, M. Neumann, R. Holle, B. Salmons, V. Erfle, and R. Brack-Werner. 1998. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J. Gen. Virol. 79:731-740. [PubMed] 30. Weinberg, A., and S. C. Holt. 1990. Interaction of Treponema denticola TD-4, GM-1, and MS25 with human gingival fibroblasts. Infect. Immun. 58:1720-1729. [PubMed] 31. Zambon, J. J. 1990. Microbiology of periodontal disease, p. 147-160. In R. J. Genco, H. M. Goldman, and D. W. Cohen (ed.), Contemporary periodontics. Mosby, St. Louis, Mo. |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||
Clin Microbiol Rev. 2001 Oct; 14(4):727-52, table of contents.
[Clin Microbiol Rev. 2001]Curr Opin Microbiol. 1998 Feb; 1(1):88-95.
[Curr Opin Microbiol. 1998]Ann Periodontol. 1998 Jul; 3(1):233-50.
[Ann Periodontol. 1998]J Periodontol. 1982 Sep; 53(9):550-6.
[J Periodontol. 1982]Adv Dent Res. 1988 Nov; 2(2):275-83.
[Adv Dent Res. 1988]Semin Respir Infect. 2001 Mar; 16(1):4-10.
[Semin Respir Infect. 2001]Infect Immun. 2000 May; 68(5):2907-15.
[Infect Immun. 2000]Infect Immun. 1998 Sep; 66(9):4222-8.
[Infect Immun. 1998]Oral Microbiol Immunol. 1990 Dec; 5(6):315-9.
[Oral Microbiol Immunol. 1990]J Periodontal Res. 1998 Feb; 33(2):91-8.
[J Periodontal Res. 1998]J Biol Chem. 1998 Jun 19; 273(25):15661-6.
[J Biol Chem. 1998]Br J Vener Dis. 1971 Dec; 47(6):413-8.
[Br J Vener Dis. 1971]Infect Immun. 1990 Jun; 58(6):1720-9.
[Infect Immun. 1990]J Bacteriol. 1976 Nov; 128(2):616-22.
[J Bacteriol. 1976]Infect Immun. 1999 Jun; 67(6):2740-5.
[Infect Immun. 1999]Infect Immun. 1999 Jun; 67(6):3121-7.
[Infect Immun. 1999]Infect Immun. 1998 Sep; 66(9):4222-8.
[Infect Immun. 1998]Rev Infect Dis. 1985 May-Jun; 7 Suppl 2():S314-7.
[Rev Infect Dis. 1985]J Clin Microbiol. 1998 Feb; 36(2):362-6.
[J Clin Microbiol. 1998]J Immunol. 1988 Apr 15; 140(8):2686-94.
[J Immunol. 1988]J Gen Virol. 1998 Apr; 79 ( Pt 4)():731-40.
[J Gen Virol. 1998]Oral Microbiol Immunol. 1997 Dec; 12(6):372-6.
[Oral Microbiol Immunol. 1997]Infect Immun. 1997 Aug; 65(8):3199-202.
[Infect Immun. 1997]Oral Microbiol Immunol. 2001 Jun; 16(3):185-7.
[Oral Microbiol Immunol. 2001]Microbiology. 1996 Apr; 142 ( Pt 4)():955-61.
[Microbiology. 1996]Microbios. 1988; 53(215):83-90.
[Microbios. 1988]Infect Immun. 1992 Nov; 60(11):4491-5.
[Infect Immun. 1992]